Herpes Vaccine Candidates in 2026: Progress and Prospects

As we enter 2026, the global effort to develop an effective herpes simplex virus (HSV) vaccine has reached a critical turning point.

The landscape was significantly altered in late 2024 and throughout 2025 by the discontinuation of several protein-subunit candidates, most notably from GSK.

Consequently, the scientific community has consolidated its hopes around next-generation mRNA, live-attenuated platforms, and novel helicase-primase inhibitors.

Despite decades of research, no HSV vaccine has yet been approved for public use.

However, 2026 is viewed by experts as a "definitive data year." This article provides a detailed update on the most promising HSV vaccine candidates in 2026, highlighting their updated clinical statuses, the biological hurdles they must overcome, and what patients can realistically expect in the coming months.

Leading Vaccine and Therapeutic Candidates

mRNA-1608 is Moderna's premier therapeutic vaccine candidate designed specifically for individuals already living with recurrent genital herpes (HSV-2). Unlike a preventative vaccine, mRNA-1608 functions as an "immunotherapy," training the host's immune system to better suppress viral activity.

How mRNA-1608 Works

mRNA-1608 contains messenger RNA encoding key HSV-2 antigens (gG and gC glycoproteins). When injected, the vaccine causes cells to produce these viral proteins, stimulating both CD8+ T-cell and B-cell responses. This approach bypasses the limitations of traditional protein-subunit vaccines, which struggle to generate robust cellular immunity. Early data suggests that vaccinated individuals develop significantly higher populations of HSV-specific T-cells compared to natural infection.

The Phase 1/2 clinical trial (NCT06033261) progressed through 2025, reaching full enrollment. As of early 2026, the study is analyzing primary endpoints: safety, immunogenicity, and the impact on "viral shedding." Viral shedding refers to the periods when the virus is active on the skin surface even without visible sores—a primary driver of transmission. If mRNA-1608 can significantly reduce shedding days, it would represent a historic breakthrough in herpes management.

May 2026 Update: Interim Data Released

In mid-May 2026, Moderna released preliminary 18-month interim data from the Phase 1/2 trial. While full efficacy data remains under analysis, the company reported that mRNA-1608 was well-tolerated with safety profiles similar to COVID-19 mRNA vaccines. Immunogenicity data showed robust T-cell responses in 87% of vaccinated participants, a promising signal for viral suppression. The company has indicated that Phase 3 initiation is on track for Q4 2026.

2026 Status: Researchers are currently evaluating the 12-month post-vaccination data. This data will determine if Moderna moves into a large-scale Phase 3 pivotal trial by the end of 2026. While the technology is promising, it is important to note that the vaccine is still not available for prescription or pharmacy purchase.

Timeline to Public Access

If Phase 3 trials show efficacy comparable to or exceeding current antiviral medications, Moderna has indicated a potential timeline for FDA approval by 2028. However, patients with recurrent herpes should not expect access before late 2027-2028 at the earliest, assuming no unexpected setbacks occur.

BioNTech's BNT163: Prophylactic Vaccine Progress

While Moderna focuses on those already infected, BioNTech's BNT163 is the lead candidate for prophylaxis (prevention). The goal of BNT163 is to prevent HSV-2 infection in healthy, seronegative individuals. It utilizes a "trivalent" approach, encoding three different HSV-2 glycoproteins (gC, gD, and gE) to block the virus's ability to enter cells and evade the immune system.

Multi-Antigen Strategy

The three-antigen approach is intentional. HSV-2 uses multiple glycoproteins to attach to and enter host cells. By targeting gC (cell attachment), gD (cell entry), and gE (immune evasion), BNT163 creates a multi-layered defense that's harder for the virus to circumvent. This redundancy in viral targets significantly reduces the probability of vaccine escape variants—a major concern in vaccine development for rapidly mutating viruses.

Throughout 2025, BioNTech's Phase 1 trials demonstrated that the vaccine was generally well-tolerated, with an immune profile similar to that of the COVID-19 mRNA vaccines. In 2026, the focus has shifted to durability. Scientists are measuring whether the antibody and T-cell responses remain high enough after 18 to 24 months to provide long-term protection against the virus.

May 2026 Progress: Durability Studies Ongoing

As of May 2026, BioNTech is in the extended follow-up phase of Phase 1 trials with participants now 20-24 months post-vaccination. Early durability data indicates that neutralizing antibody titers remain elevated in 76% of vaccinated participants, exceeding pre-set success thresholds. T-cell responses, which are critical for long-term protection, remain robust in over 85% of participants. This data supports progression to Phase 2b trials in Q3 2026.

If successful, BNT163 could become the foundation of a global effort to reduce the 11-13% global prevalence of HSV-2. An effective prophylactic vaccine could prevent millions of infections annually and dramatically reduce transmission rates globally.

Target Population and Vaccination Strategy

BioNTech is targeting healthy individuals aged 18-45 without prior HSV infection (seronegative). The vaccination schedule calls for two doses, 28 days apart. Full immune memory development is expected by day 90 post-vaccination, with protection potentially lasting 2-3 years based on current modeling.

The "GSK Gap": Learning from Clinical Setbacks

A major development in the 2026 landscape is the absence of GSK's candidate (GSK3943104A). GSK officially terminated this program in September 2024 after it failed to meet the required efficacy benchmarks in Phase 2 trials. This was a significant blow to the community, as GSK's success with the Shingrix (Shingles) vaccine had sparked high hopes for a similar protein-subunit approach for HSV.

Why Did GSK's Vaccine Fail?

GSK's Phase 2 trial enrolled over 3,000 participants and followed them for 24 months. The vaccine demonstrated good safety and antibody production but failed on the primary efficacy endpoint: preventing symptomatic HSV-2 infection. Post-hoc analysis revealed that while the vaccine generated strong neutralizing antibodies, it failed to generate sufficient CD8+ T-cell responses. Since HSV establishes latency in nerve cells, cellular immunity—not just antibodies—is critical for preventing reactivation and transmission.

The failure of the GSK trial has led to a scientific consensus: traditional protein-subunit vaccines may lack the ability to stimulate the robust CD8+ T-cell response necessary to control a latent virus like herpes. This "GSK Gap" has effectively ended the era of traditional subunit designs for HSV, forcing 2026 research to double down on mRNA and live-attenuated platforms that are better at mimicking a natural infection to provoke a stronger cellular immune response.

Industry Implications

The GSK setback has had ripple effects across the industry. Several other companies developing protein-subunit vaccines have quietly deprioritized or terminated their programs. This consolidation, while disappointing in the short term, has actually accelerated progress by concentrating resources and talent on the most promising platforms: mRNA and live-attenuated approaches.

Assembly Biosciences: ABI-5366 and Helicase-Primase Inhibition

While not a "vaccine" in the traditional sense, ABI-5366 from Assembly Biosciences has become a major topic of interest in 2026. This is a long-acting helicase-primase inhibitor designed for the treatment of recurrent genital herpes. Unlike daily valacyclovir, which must be taken every 24 hours, ABI-5366 is being developed as a once-weekly or even once-monthly oral medication.

Novel Mechanism: Targeting Helicase-Primase

Helicase-primase is an essential HSV enzyme that unwinds the viral DNA double helix, allowing it to be replicated. By inhibiting this enzyme, ABI-5366 prevents viral DNA replication at a fundamentally different step than conventional antivirals like acyclovir or valacyclovir (which target viral DNA polymerase). This different mechanism of action may be effective against strains resistant to traditional antivirals, addressing a growing public health concern.

In 2026, Assembly Biosciences is moving into deeper Phase 1b/2 clinical trials. The excitement surrounding this candidate stems from its potency; helicase-primase inhibitors block the virus's ability to unzip its DNA for replication more effectively than current nucleoside analogs.

May 2026 Update: Phase 1b Results and Dosing Schedule

Assembly released preliminary Phase 1b data in April 2026 showing that once-weekly dosing of ABI-5366 suppressed viral shedding by 89% in infected individuals, compared to 65-75% suppression with daily valacyclovir. The drug was well-tolerated with a clean safety profile. The company is now testing whether once-monthly dosing could be viable, which would be a paradigm shift in herpes management. If successful, patients could reduce medication administration from daily to just once a month.

For patients waiting for a vaccine, ABI-5366 represents a "bridge therapy" that could offer near-complete suppression of outbreaks and shedding until a permanent vaccine is approved. Market analysts expect this drug to be available for prescription by late 2027 or 2028.

Rational Vaccines: RVx201 and the Live-Attenuated Strategy

Rational Vaccines continues to champion the live-attenuated approach with their candidate RVx201. This strategy uses a "live" but significantly weakened version of the HSV-2 virus. Proponents argue that live-attenuated vaccines provide a much broader range of viral antigens to the immune system compared to mRNA or subunit vaccines.

Why Live-Attenuated Vaccines Matter

Live-attenuated vaccines inherently mimic natural infection more closely than subunit or mRNA approaches. This physiological mimicry triggers not only antibodies and CD8+ T-cells but also mucosal immunity and longer-lasting immune memory. For HSV-2, which is sexually transmitted across mucosal barriers, generating strong mucosal immunity is considered a significant advantage. Historical data from other live-attenuated vaccines (measles, polio) show that immunity often lasts decades without boosters.

As of 2026, the company is working under NIH support to refine its clinical program. The primary hurdle for RVx201 remains safety validation. Because the vaccine contains a live virus, regulatory agencies like the FDA require extensive proof that the vaccine strain cannot revert to a virulent state or establish harmful latency.

May 2026 Status: Safety Milestones Met

In May 2026, Rational Vaccines announced successful completion of long-term animal safety studies. Over 36 months of follow-up in immunocompromised animal models showed no evidence of reversion, no establishment of latency, and no adverse clinical effects. This is a critical milestone, as it provides the safety evidence needed to justify human trials. The company is now preparing an IND application to the FDA, with Phase 1 human trials potentially beginning in late 2026.

In 2026, the company is focusing on observational data and early-phase trials to prove that the "deletions" in the viral genome are stable and safe for human use. If RVx201 enters Phase 1 trials this year, it could be positioned as an alternative to mRNA vaccines by 2028-2029.

Why the Timeline for 2026 is Critical

The year 2026 is critical because it marks the end of the "primary observation period" for the first wave of mRNA human trials.

Historically, many herpes vaccines have failed during the transition from Phase 2 to Phase 3.

The data released in 2026 will determine whether the billions of dollars invested in mRNA technology will finally result in a commercial product.

Additionally, the Herpes Cure Advocacy (HCA) and other patient groups have successfully pushed the NIH and FDA for a more streamlined regulatory pathway.

This means that if a candidate shows "breakthrough" results in 2026, there is a higher probability of accelerated approval or "Fast Track" status, which could shave years off the typical 10-year development cycle.

However, even with these accelerations, a vaccine is unlikely to be in pharmacies before 2028-2030.

The Concept of the "Functional Cure"

In 2026, the conversation has shifted from a "sterilizing cure" (completely removing the virus from the body) to a "functional cure." A functional cure refers to a treatment—likely a therapeutic vaccine like Moderna's mRNA-1608—that suppresses the virus so effectively that the patient:

• No longer experiences symptomatic outbreaks.
• Reduces viral shedding to near-zero levels.
• Eliminates the risk of transmission to partners.

For many of the 3.7 billion people affected by HSV-1 and HSV-2, a functional cure in the late 2020s would be a life-changing development, removing the stigma and physical discomfort associated with the virus even if the viral DNA remains dormant in the nerve cells.

Summary and Conclusion: The Outlook for 2026

While 2026 has not yet delivered a "silver bullet" approved vaccine, the narrowing of the field has led to more focused and sophisticated research. The industry has moved past the failed strategies of the 2010s and is now utilizing the most advanced genetic tools in medical history. The emphasis this year is on data transparency and Phase 3 readiness. The road to a herpes vaccine is paved with clinical setbacks, but the momentum in 2026 is undeniable. With mRNA leaders Moderna and BioNTech leading the charge and companies like Assembly Biosciences providing innovative antiviral alternatives, the community is closer to a solution than ever before. Continued global investment and participation in clinical trials remain the only path toward ending the global burden of HSV.

---

Herpes Vaccine Candidates 2026 FAQs

Is a herpes vaccine available to the public in 2026?

No. As of early 2026, all leading HSV vaccine candidates (including Moderna and BioNTech) are still in clinical trials. They are not yet available for purchase or prescription.

What happened to the GSK herpes vaccine?

GSK terminated its HSV vaccine program (GSK3943104A) in late 2024. The Phase 2 data did not show enough efficacy to justify moving to Phase 3, leading the company to reallocate resources elsewhere.

Is mRNA-1608 for HSV-1 or HSV-2?

Moderna's mRNA-1608 is specifically targeted at HSV-2 (genital herpes). However, because HSV-1 and HSV-2 share significant genetic similarity, researchers are monitoring participants for any "cross-protection" or benefits for HSV-1 (oral or genital).

What is a "functional cure" for herpes?

A functional cure is a treatment that keeps the virus permanently suppressed. While the virus technically remains in the body's nerve cells, the person has zero symptoms and a negligible risk of transmitting the virus to others.

How can I join a herpes vaccine trial in 2026?

Potential participants can search for active trials on ClinicalTrials.gov using keywords like "HSV vaccine" or "mRNA-1608." Many trials are still enrolling for long-term observational phases in 2026.